Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNotes PayablesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Universe Pharmaceuticals (UPC) Cash & Equivalents (2020 - 2025)

Universe Pharmaceuticals' Cash & Equivalents history spans 6 years, with the latest figure at $33.6 billion for Q3 2025.

  • For Q3 2025, Cash & Equivalents rose 113780.18% year-over-year to $33.6 billion; the TTM value through Sep 2025 reached $33.6 billion, up 113780.18%, while the annual FY2025 figure was $33.6 billion, 113780.18% up from the prior year.
  • Cash & Equivalents for Q3 2025 was $33.6 billion at Universe Pharmaceuticals, up from $29.5 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $33.6 billion in Q3 2025 and bottomed at $8.1 million in Q3 2021.
  • The 5-year median for Cash & Equivalents is $5.3 billion (2023), against an average of $8.9 billion.
  • The largest annual shift saw Cash & Equivalents crashed 99.44% in 2024 before it soared 113780.18% in 2025.
  • A 5-year view of Cash & Equivalents shows it stood at $8.1 million in 2021, then surged by 70604.67% to $5.7 billion in 2022, then dropped by 7.46% to $5.3 billion in 2023, then plummeted by 99.44% to $29.5 million in 2024, then skyrocketed by 113780.18% to $33.6 billion in 2025.
  • Per Business Quant, the three most recent readings for UPC's Cash & Equivalents are $33.6 billion (Q3 2025), $29.5 million (Q3 2024), and $5.3 billion (Q3 2023).